Artera is an AI-powered precision medicine platform that predicts cancer treatment outcomes by analyzing both pathology images and clinical data. Designed to help oncologists tailor therapies to individual patients, Artera supports clinical decision-making in prostate cancer and aims to expand across oncology.
Its flagship product, ArteraAI Prostate, is the first and only FDA-cleared AI prognostic test that predicts therapy benefit for localized prostate cancer. Using multimodal deep learning, Artera combines digitized biopsy slides with patient data to generate a personalized risk score, helping physicians determine whether a patient is likely to benefit from androgen deprivation therapy (ADT) in addition to radiation.
With its groundbreaking approach, Artera is changing how personalized medicine is delivered in oncology—by offering data-driven insights at the point of care.
Features
Artera’s AI platform is built to support clinicians and health systems with a variety of advanced capabilities:
Multimodal AI Models: Combine pathology images and structured clinical data for comprehensive analysis.
FDA-Cleared Prognostic Tool: ArteraAI Prostate is validated to predict treatment benefit and disease progression.
Personalized Risk Scores: Provide individualized predictions of therapy response and long-term outcomes.
Clinical Decision Support: Helps oncologists personalize treatment plans (e.g., ADT duration decisions).
Biopsy Slide Digitization: Utilizes scanned H&E-stained slides to enable AI analysis.
Seamless Provider Integration: Works with urologists, oncologists, and pathology labs to deliver reports quickly.
Fast Turnaround Time: Results typically available within 5–7 business days.
Regulatory Compliance: Meets FDA standards for diagnostic use and clinical validity.
Accessible Nationwide: Testing available across the U.S. with sample logistics support.
Data Security: HIPAA-compliant and secured to protect patient privacy.
How It Works
Artera’s process integrates digital pathology with AI to provide actionable insights. Here’s how it works:
Tissue Sample Collection: A prostate biopsy slide is collected and stained (H&E) as part of routine diagnosis.
Slide Digitization: The slide is scanned and converted into a high-resolution digital image.
Clinical Data Submission: Providers submit relevant clinical data (e.g., PSA level, Gleason score).
AI Analysis: Artera’s multimodal AI model processes both the image and clinical data to generate a personalized risk prediction.
Results Delivery: A comprehensive report is returned to the physician within a few days, outlining therapy benefit predictions and risk assessments.
This enables oncologists to determine whether adding ADT to radiation therapy will benefit the patient or lead to unnecessary side effects.
Use Cases
Artera is designed to assist oncology professionals across a range of clinical scenarios:
Localized Prostate Cancer Treatment Planning: Decide whether ADT should be added to radiotherapy.
Prognostic Risk Stratification: Understand a patient’s likelihood of recurrence or disease progression.
ADT Duration Decisions: Guide the length of hormone therapy based on predicted benefit.
Treatment De-Escalation: Avoid overtreatment in low-risk patients with limited benefit from ADT.
Multidisciplinary Team Coordination: Align urologists, oncologists, and radiologists with a unified risk assessment.
Patient Counseling: Provide patients with clear, personalized information to support shared decision-making.
Pricing
Artera does not publish specific pricing on its website. However, its test—ArteraAI Prostate—may be reimbursed by private insurers and Medicare depending on medical necessity and region.
Key pricing details include:
Reimbursement: Some insurers cover the test; coverage is expanding with ongoing partnerships.
Out-of-Pocket Cost: Patients without insurance may be eligible for financial assistance programs.
Billing Support: Artera’s team provides direct assistance to patients and providers for insurance verification.
Clinicians and patients are encouraged to contact Artera directly for the latest pricing and coverage options via the Artera contact page.
Strengths
Artera offers several key advantages that position it at the forefront of AI-enabled precision oncology:
First and only FDA-cleared AI model in prostate cancer therapy guidance
Multimodal data integration leads to highly personalized insights
Enables precision treatment with improved outcomes and fewer side effects
Fast, accessible test with national logistics support
Backed by clinical validation and peer-reviewed studies
Supports treatment de-escalation in low-risk patients
Improves provider and patient confidence in therapy planning
Strong partnerships with cancer centers and academic institutions
Drawbacks
While Artera is highly innovative, a few limitations should be noted:
Currently limited to prostate cancer—expansion to other cancers is in progress
Requires digitized biopsy slides, which may not be available in all pathology labs
Adoption depends on clinician education and workflow integration
AI model explainability may be a barrier for some providers unfamiliar with ML tools
Reimbursement not yet universal, though growing
Comparison with Other Tools
Artera operates in a specialized niche of AI-enabled pathology for cancer treatment personalization. Comparable tools include:
Decipher by Veracyte: Genomic-based risk test for prostate cancer; uses RNA signatures rather than image-based AI.
Oncotype DX: Genomic assay used in breast and prostate cancer; requires molecular testing.
Paige AI: Focused on pathology detection and cancer diagnosis, not treatment prediction.
PathAI: Primarily supports diagnosis accuracy and pathology workflow, not therapy decisioning.
Artera’s unique value lies in its non-genomic, multimodal AI approach that integrates pathology and clinical data to guide treatment, not just diagnosis—and it’s the only platform in this space with FDA clearance for this purpose.
Customer Reviews and Testimonials
While there are no public reviews on platforms like G2 or Trustpilot, Artera features endorsements and clinical partnerships with major academic and cancer centers.
Testimonials from physicians include:
“Artera’s test gives me clarity in deciding which patients truly benefit from ADT.”
“Having FDA clearance gives us the confidence to use it routinely in care planning.”
“This is the future of personalized oncology—AI that works directly with clinical workflows.”
The company has also presented clinical validation at major oncology conferences and in peer-reviewed journals, demonstrating strong adoption in prostate cancer care.
Conclusion
Artera is reshaping precision oncology through the power of multimodal AI. By combining clinical and pathology data into a single predictive platform, Artera empowers oncologists to make more accurate, personalized treatment decisions—starting with localized prostate cancer.
Its FDA-cleared platform represents a major step forward in applying AI not just for diagnosis, but for predicting treatment benefit and minimizing unnecessary therapy. With a rapidly growing footprint and a strong foundation in clinical science, Artera is poised to lead the next wave of AI-enabled cancer care.
For oncologists and healthcare systems aiming to bring precision medicine into daily practice, Artera offers a tested, validated, and deployable solution ready for real-world impact.
